10 results
The research question of the main study is: What are the short- and long-term effects and costs of helmet treatmentcompared to a wait-and-see regimen for a period of 6 months on skull asymmetry in children withmoderate to severe DP.The objective of…
If proven (cost)effective, without inducing antivral resistance, oseltamivir could have considerable benefits in this setting, although constraints relating to implementation need to be addressed as well. If not (cost)effective if this fragile…
Primary: To assess the antiviral efficacy of triple combination antiviral drug (TCAD) therapy(i.e. amantadine and ribavirin co-administered with oseltamivir) compared to oseltamivirmonotherapy in immunocompromised subjects diagnosed with Influenza…
Dividing the study population in four categories (oncological patients, critically ill patients admitted to intensive care, neonates and other children) answers to the following questions are sought:- which initial dosage regimen for vancomycin…
Primary: To determine the safety and tolerability of TCAD administered orally to immunocompromised patients diagnosed with influenza ASecondary: To assess the antiviral effect, the speed of symptom resolution, and the influenza complication rate of…
The hypothesis is that a switch from intravenous to oral antimicrobial therapy is non-inferior to standard intravenous therapy in patients with low-risk SAB. Therefore, the primary objective of the trial is to demonstrate, that oral switch therapy (…
The primary objectives are to determine the inhibitory effect of intravenously administered C1-inhibitor as well as the influence of depletion of the human microbiota on allergic lung inflammation induced by house dust mite (HDM) plus…
Primary• Evaluate the efficacy of 8 weeks of treatment with VE202 in terms of endoscopic response at Day 56 • Evaluate the safety of VE202 in Part 1 and Part 2 of the study Secondary objectiveSecondary objective1. Evaluate the safety of VE202 in…
To determine whether 4 weeks of total antibiotic treatment duration is non-inferior to 6 weeks in patients with complicated SAB who have responded well to the initial treatment.
To assess the influence of dosing guided by AutoK on achieving PK targets and clinical endpoints in intensive care patients with sepsis.